Microbial cancer therapeutics: A promising approach

Diwan, Deepti; Cheng, Lei; Usmani, Zeba; Sharma, Minaxi; Holden, Nicola; Willoughby, Nicholas; Sangwan, Rajender Singh; Baadhe, Rama Raju; Liu, Chenchen; Gupta, Vijai Kumar

doi:10.1016/j.semcancer.2021.05.003

Cited by 18 publications

(9 citation statements)

References 337 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aurilides are reported to be potently cytotoxic toward murine neural crest-derived cancer cells (Neuro-2a), a cervical cancer cell line (HeLa), and NCI-60 cell lines, a cell panel created by the U.S. National Cancer Institute to characterize the genomic markers of drug sensitivity [ 47 ]. Hence, they serve as promising chemotherapeutic agents [ 43 , 48 ].…”

Section: Depsipeptides With a Recognized Mechanism Of Targeting Cance...mentioning

confidence: 99%

“…Furthermore, largazole demonstrated potent antiproliferative effects by stimulating histone hyperacetylation in tumor cells, subsequently inducing cell cycle arrest, in cells of colon cancer (HCT116), fibroblastic osteosarcoma (U2OS), glioblastoma multiforme (SF-268 and SF-295), neuroblastoma (IMR-32 and SH-SY5Y), and multiple NCI-60 cell lines [ 48 , 128 ].…”

Section: Depsipeptides With a Recognized Mechanism Of Targeting Cance...mentioning

confidence: 99%

“…Both lyngbyabellin A and E possess potent actin polymerization activity [ 129 ]. They induce cell cycle arrest in the human Burkitt lymphoma (BL) cell line [ 48 ], e.g., lyngbyabellin B arrests BL cells in the G 2 /M phase [ 130 ]. Lyngbyabellin E showed significant activity against human lung tumors (NCI-H460) and Neuro-2a cell lines [ 131 ], and lyngbyabellin N against colorectal carcinoma cells (HCT116) [ 44 ].…”

Section: Depsipeptides With a Recognized Mechanism Of Targeting Cance...mentioning

confidence: 99%

“…Sansalvamide A arrests cells in the G 1 phase, inhibits topoisomerase I [ 21 , 135 ], and subsequently triggers apoptosis of tumor cells [ 48 ]. It causes in vitro pancreatic cancer cell death by downregulating cyclins A, CD4, D1, E, and upregulating p21, resulting in cell cycle arrest in the G 0 /G 1 phase [ 13 , 135 ].…”

Section: Depsipeptides With a Recognized Mechanism Of Targeting Cance...mentioning

confidence: 99%

See 3 more Smart Citations

Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials

2023

View full text Add to dashboard Cite

Cancer is currently considered one of the most threatening diseases worldwide. Diet could be one of the factors that can be enhanced to comprehensively address a cancer patient’s condition. Unfortunately, most molecules capable of targeting cancer cells are found in uncommon food sources. Among them, depsipeptides have emerged as one of the most reliable choices for cancer treatment. These cyclic amino acid oligomers, with one or more subunits replaced by a hydroxylated carboxylic acid resulting in one lactone bond in a core ring, have broadly proven their cancer-targeting efficacy, some even reaching clinical trials and being commercialized as “anticancer” drugs. This review aimed to describe these depsipeptides, their reported amino acid sequences, determined structure, and the specific mechanism by which they target tumor cells including apoptosis, oncosis, and elastase inhibition, among others. Furthermore, we have delved into state-of-the-art in vivo and clinical trials, current methods for purification and synthesis, and the recognized disadvantages of these molecules. The information collated in this review can help researchers decide whether these molecules should be incorporated into functional foods in the near future.

show abstract

Section: Depsipeptides With a Recognized Mechanism Of Targeting Cance...mentioning

confidence: 99%

Section: Depsipeptides With a Recognized Mechanism Of Targeting Cance...mentioning

confidence: 99%

Section: Depsipeptides With a Recognized Mechanism Of Targeting Cance...mentioning

confidence: 99%

Section: Depsipeptides With a Recognized Mechanism Of Targeting Cance...mentioning

confidence: 99%

See 2 more Smart Citations

Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials

2023

View full text Add to dashboard Cite

show abstract

“…Genomic instability and phenotypic heterogeneity inherent in each malignant tissue [ 1 ] render the treatment of cancer extremely challenging [ 2 ]. Today, apart from surgical operation, a variety of promising therapeutic strategies have been developed, including but not limited to radiotherapy [ 3 ], chemotherapy [ 4 ], biological therapy [ 5 ], immunotherapy [ 6 ], and microbial-based therapy [ 7 , 8 ]. From this ever-growing curative armamentarium, targeted chemotherapy with small-molecule or biomacromolecular agents is an indispensable measure [ 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Anticancer Small-Molecule Agents Targeting Eukaryotic Elongation Factor 1A: State of the Art

Zhang

Cai

et al. 2023

IJMS

View full text Add to dashboard Cite

Eukaryotic elongation factor 1A (eEF1A) canonically delivers amino acyl tRNA to the ribosomal A site during the elongation stage of protein biosynthesis. Yet paradoxically, the oncogenic nature of this instrumental protein has long been recognized. Consistently, eEF1A has proven to be targeted by a wide assortment of small molecules with excellent anticancer activity, among which plitidepsin has been granted approval for the treatment of multiple myeloma. Meanwhile, metarrestin is currently under clinical development for metastatic cancers. Bearing these exciting advances in mind, it would be desirable to present a systematic up-to-date account of the title topic, which, to the best of our knowledge, has thus far been unavailable in the literature. The present review summarizes recent advances in eEF1A-targeting anticancer agents, both naturally occurring and synthetically crafted, with regard to their discovery or design, target identification, structure–activity relationship, and mode of action. Their structural diversity and differential eEF1A-targeting mechanisms warrant continuing research in pursuit of curing eEF1A-driven malignancy.

show abstract

Genetically Engineered Bacteria as A Living Bioreactor for Monitoring and Elevating Hypoxia‐Activated Prodrug Tumor Therapy

Zhang,

Chen,

Chen

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Tirapazamine (TPZ), an antitumor prodrug, can be activated in hypoxic environment. It specifically targets the hypoxic microenvironment of tumors and produces toxic free radicals. However, due to the tumor is not completely hypoxic, TPZ often fails to effectively treat the entire tumor tissue, resulting in suboptimal therapeutic outcomes. Herein, a low pathogenic Escherichia coli TOP10 is utilized to selectively colonize tumor tissues, disrupt blood vessels, and induce thrombus formation, leading to the expansion of hypoxic region and improving the therapeutic effect of TPZ. Additionally, a thermosensitive hydrogel is constructed by Pluronic F‐127 (F127), which undergoes gelation in situ at the tumor site, resulting in sustained release of TPZ. To monitor the therapeutic process, it is genetically modified TOP10 by integrating the bioluminescent system luxCDABE (TOP10‐Lux). The bioluminescent signal is associated with tumor hypoxia enhancement and thrombus formation, which is beneficial for therapeutic monitoring with bioluminescence imaging. In the murine colon cancer model, the TOP10‐Lux combined with TPZ‐loaded F127 hydrogel effectively suppressed tumor growth, and the treatment process is efficiently monitored. Together, this work employs genetically modified TOP10‐Lux to enhance the therapeutic efficacy of TPZ and monitor the treatment process, providing an effective strategy for bacteria‐based tumor‐targeted chemotherapy and treatment monitoring.

show abstract

Microbial cancer therapeutics: A promising approach

Cited by 18 publications

References 337 publications

Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials

Depsipeptides Targeting Tumor Cells: Milestones from In Vitro to Clinical Trials

Anticancer Small-Molecule Agents Targeting Eukaryotic Elongation Factor 1A: State of the Art

Genetically Engineered Bacteria as A Living Bioreactor for Monitoring and Elevating Hypoxia‐Activated Prodrug Tumor Therapy

Contact Info

Product

Resources

About